What's on this Page
Dimethyl Fumarate Brand Name– Tecfidera
What is Dimethyl Fumarate
Dimethyl fumarate is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Dimethyl fumarate appears to have neuroprotective and anti-inflammatory properties; these actions can help delay disability and disease progression.
In the pivotal pre-approval trial, dimethyl fumarate 240 mg twice daily led to significant reductions in the annualized relapse rate over 2 years (0.17) as compared with placebo (0.36).
The trial also showed a 38% decrease in risk of disability progression with treatment (p=0.005) and a significant improvement in quality of life scores as early as week 24.
Similar results were found in another phase 3 trial: the annualized relapse rate over 2 years was significantly lower with dimethyl fumarate vs. placebo
Indications
- multiple sclerosis
For the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Side Effects
- abdominal pain
- anaphylactoid reactions
- angioedema
- diarrhea
- dyspepsia
- elevated hepatic enzymes
- eosinophilia
- erythema
- flushing
- flushing
- infection
- leukoencephalopathy
- leukopenia
- lymphopenia
- lymphopenia
- nausea
- progressive multifocal leukoencephalopathy
- proteinuria
- pruritus
- rash
- vomiting
Monitoring Parameters
- CBC with differential
- LFTs
- serum bilirubin
Contraindications
- breast-feeding
- hepatic disease
- hepatotoxicity
- immunosuppression
- pregnancy
- progressive multifocal leukoencephalopathy
Interactions
- Diroximel Fumarate
- Ocrelizumab
